Quadruple rescue therapy for Helicobacter pylori infection after two treatment failuresHSU, P. I; WU, D. C; CHEN, A et al.European journal of clinical investigation. 2008, Vol 38, Num 6, pp 404-409, issn 0014-2972, 6 p.Article

Characterization of HIV-1 antiretroviral drug resistance after second-line treatment failure in Mali, a limited-resources settingISSIAKA MAIGA, Almoustapha; BOCAR FOFANA, Djeneba; MURPHY, Robert et al.Journal of antimicrobial chemotherapy (Print). 2012, Vol 67, Num 12, pp 2943-2948, issn 0305-7453, 6 p.Article

Third-line antiepileptic therapy and outcome in status epilepticus: The impact of vasopressor use and prolonged mechanical ventilationKOWALSKI, Robert G; ZIAI, Wendy C; REES, Richard N et al.Critical care medicine. 2012, Vol 40, Num 9, pp 2677-2684, issn 0090-3493, 8 p.Article

A phase II study of tasisulam sodium (LY573636 sodium) as second-line or third-line treatment for patients with unresectable or metastatic soft tissue sarcomaRYAN, Christopher W; MATIAS, Chacon; KEOHAN, M. L et al.Investigational new drugs. 2013, Vol 31, Num 1, pp 145-151, issn 0167-6997, 7 p.Article

Third-Line Agent Selection for Patients with Type 2 Diabetes Mellitus Uncontrolled with Sulfonylureas and MetforminEDWARDS, Krystal L; ALVAREZ, Carlos; IRONS, Brian K et al.Pharmacotherapy. 2008, Vol 28, Num 4, pp 506-521, issn 0277-0008, 16 p.Article

Evaluation of Amrubicin as a Third or Later Line of Chemotherapy for Advanced Non-Small Cell Lung CancerIGAWA, Satoshi; SASAKI, Jiichiro; ISHIHARA, Mikiko et al.Chemotherapy (Basel). 2013, Vol 59, Num 2, pp 99-105, issn 0009-3157, 7 p.Article

Sequential Inhibitor Therapy in CML: In Vitro Simulation Elucidates the Pattern of Resistance Mutations after Second- and Third-Line TreatmentBAUER, Robert C; SÄNGER, Jana; PESCHEL, Christian et al.Clinical cancer research (Print). 2013, Vol 19, Num 11, pp 2962-2972, issn 1078-0432, 11 p.Article

Usefulness of chemotherapy beyond the second line for metastatic breast cancer: a therapeutic challengeVAULEON, Elodie; MESBAH, Habiba; LAGUERRE, Brigitte et al.Cancer chemotherapy and pharmacology. 2010, Vol 66, Num 1, pp 113-120, issn 0344-5704, 8 p.Article

The Need for Third-line Treatment in Non-small Cell Lung Cancer: An Overview of New OptionsSYRIGOS, Kostas N; SAIF, Muhammad W; KARAPANAGIOTOU, Eleni M et al.Anticancer research. 2011, Vol 31, Num 2, pp 649-659, issn 0250-7005, 11 p.Article

Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II studyTIEN HOANG; CAMPBELL, Toby C; JOHNSON, Peter H et al.Investigational new drugs. 2014, Vol 32, Num 1, pp 195-199, issn 0167-6997, 5 p.Article

Treatment outcome and cost-effectiveness of different highly active antiretroviral therapy regimens in the UK (1996-2002)BECK, E. J; MANDALIA, S; WALSH, J et al.International journal of STD & AIDS. 2008, Vol 19, Num 5, pp 297-304, issn 0956-4624, 8 p.Article

Increased dihydropyrimidine dehydrogenase activity in breast cancerANAN, Keisei; MITSUYAMA, Shoshu; TAMAE, Keiyoshi et al.Journal of surgical oncology. 2003, Vol 82, Num 3, pp 174-179, issn 0022-4790, 6 p.Article

Efficacy of Amrubicin for Non-small Cell Lung Cancer after Failure of Two or More Prior Chemotherapy RegimensIGAWA, Satoshi; TAKAHASHI, Toshiaki; NAKAMURA, Yukiko et al.Anticancer research. 2008, Vol 28, Num 6B, pp 3855-3858, issn 0250-7005, 4 p.Article

Genotype assays and third-line ART in resource-limited settings: a simulation and cost-effectiveness analysis of a planned clinical trialLORENZANA, Sarah B; HUGHES, Michael D; WALLIS, Carole L et al.AIDS (London). 2012, Vol 26, Num 9, pp 1085-1095, issn 0269-9370, 11 p.Article

Platinum-based doublet chemotherapy in pre-treated malignant pleural mesothelioma (MPM) patients: A mono-institutional experiencePASELLO, Giulia; NICOTRA, Samuele; MARULLI, Giuseppe et al.Lung cancer. 2011, Vol 73, Num 3, pp 351-355, issn 0169-5002, 5 p.Article

Oral second- and third-line lomustine-etoposide-cyclophosphamide chemotherapy for small cell lung cancerLEBEAU, Bernard; CHOUAÏD, Christos; BAUD, Mariette et al.Lung cancer. 2010, Vol 67, Num 2, pp 188-193, issn 0169-5002, 6 p.Article

Third-line therapy for metastatic colorectal cancerGUNDGAARD, M. G; SOERENSEN, J. B; EHRNROOTH, E et al.Cancer chemotherapy and pharmacology. 2008, Vol 61, Num 1, pp 1-13, issn 0344-5704, 13 p.Article

Third-line chemotherapy for small cell lung cancerDE JONG, Wouter K; TEN HACKEN, Nick H. T; GROEN, Harry J. M et al.Lung cancer. 2006, Vol 52, Num 3, pp 339-342, issn 0169-5002, 4 p.Article

A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancerKANG, Yoon-Koo; MURO, Kei; RYU, Min-Hee et al.Investigational new drugs. 2014, Vol 32, Num 2, pp 355-361, issn 0167-6997, 7 p.Article

Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010FELIP, E; GRIDELLI, C; BAAS, P et al.Annals of oncology. 2011, Vol 22, Num 7, pp 1507-1519, issn 0923-7534, 13 p.Article

Prevalence and effectiveness of first-, second-, and third-line systemic therapy in a cohort of unselected patients with advanced non-small cell lung cancerZIETEMANN, V; DUELL, T.Lung cancer. 2011, Vol 73, Num 1, pp 70-77, issn 0169-5002, 8 p.Article

Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer : a phase II studyDO HYOUNG LIM; YOUNG SUK PARK; WON SEOG KIM et al.Cancer chemotherapy and pharmacology. 2005, Vol 56, Num 1, pp 10-14, issn 0344-5704, 5 p.Article

Every-day clinical practice in patients with advanced non-small-cell lung cancerZIETEMANN, V; DUELL, T.Lung cancer. 2010, Vol 68, Num 2, pp 273-277, issn 0169-5002, 5 p.Article

Second and third line treatment in non-small cell lung cancerFAVARETTO, Adolfo; PASELLO, Giulia; MAGRO, Cristina et al.Critical reviews in oncology/hematology. 2009, Vol 71, Num 2, pp 117-126, issn 1040-8428, 10 p.Article

A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancerMASSARELLI, E; ANDRE, F; LIU, D. D et al.Lung cancer. 2003, Vol 39, Num 1, pp 55-61, issn 0169-5002, 7 p.Article